press release-凯发88

english 凯发88-凯发vip-娱乐凯发app下载中文繁体

english 凯发88-凯发vip-娱乐凯发app下载中文繁体

news press release media report

year:

select

press release

13 may 2020

alphamab oncology announces four ind application approvals from nmpa cde the approval of the four ind applications marks a new milestone for our continued efforts on expanding combo treatments.
16 april 2020

alphamab oncology received u.s. fda ind approval to initiate a phase ii clinical trial of kn046 for nsclc in the united states kn046's phase i clinical trials in australia and china, along with multiple phase ii trials in china have shown a good safety profile and promising efficacy.
30 march 2020

alphamab oncology, simcere and 3d medicines announce partnership to develop and commercialize subcutaneous injectable anti-pd-l1 antibody for oncology indications in mainland china this collaboration amongst three companies not only has demonstrated how top tier innovative r&d, clinical and commercial teams in china join forces, but also could set the example of an outstanding c...
27 march 2020

alphamab oncology announces clinical supply collaboration with pfizer on kn026 in combination with ibrance® (palbociclib) this phase ib/ii clinical trial is a multicenter, open-label study, aiming to evaluate efficacy, safety and tolerability of kn026 in combination with palbociclib in patients with locally advanced unre...
24 february 2020

four ind applications accepted by nmpa cde for kn046 and kn026 new therapies these ind applications mark that alphamab oncology is entering the stage of clinical study of combination therapy.
08 february 2020

jiangsu alphamab passed on-site inspection of eu qualified person alphamab oncology (stock code: 9966.hk) announced that jiangsu alphamab biopharmaceuticals co., ltd. (“jiangsu alphamab”), a wholly-owned subsidiary of the company, has passed the on-site inspection...
27 janurary 2020

alphamab donates 1 m rmb to support wuhan’s war against coronavirus bless wuhan, bless china, we all stand together with you.
22 janurary 2020

mr. yaping li, mayor of suzhou visited alphamab oncology on january 21, yaping li, mayor of suzhou and deputy secretary of the cpc suzhou municipal committee, and his delegation visited alphamab oncology to meet with dr. ting xu, the founder, chairman and c...
19 janurary 2020

us fda rewarded pd-l1 antibody kn035 with orphan drug designation the us food and drug administration (“us fda”) have rewarded orphan drug designation(“odd”) to pd-l1 antibody kn035 for the treatment of biliary tract cancer (“btc”).
09 janurary 2020

alphamab oncology completes dosing for first patient in kn026 phase ii clinical trial for breast cancer kn026-201 is a phase ii clinical study aimed to evaluate the safety and efficacy of kn026 combined with docetaxel in the first-line treatment of breast cancer with her2 expression and kn026 monotherap...

6 7 8 9 10 11 12